NCT04180371 2025-11-17Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 ExpressionBicycleTx LimitedPhase 1/2 Active not recruiting288 enrolled
NCT04278144 2025-09-15A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid TumorsBolt Biotherapeutics, Inc.Phase 1/2 Terminated175 enrolled
NCT03093116 2025-07-10TRIDENT-1Turning Point Therapeutics, Inc.Phase 1/2 Recruiting500 enrolled 2 FDA